Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Current Drug Therapy in Chronic Heart Failure: the New Guidelines of the European Society of Cardiology (ESC).

Berliner D, Bauersachs J.

Korean Circ J. 2017 Sep;47(5):543-554. doi: 10.4070/kcj.2017.0030. Epub 2017 Aug 21. Review.

2.

E2/ER β inhibit ISO-induced cardiac cellular hypertrophy by suppressing Ca2+-calcineurin signaling.

Tsai CY, Kuo WW, Shibu MA, Lin YM, Liu CN, Chen YH, Day CH, Shen CY, Viswanadha VP, Huang CY.

PLoS One. 2017 Sep 1;12(9):e0184153. doi: 10.1371/journal.pone.0184153. eCollection 2017.

3.

Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial.

Farha S, Saygin D, Park MM, Cheong HI, Asosingh K, Comhair SA, Stephens OR, Roach EC, Sharp J, Highland KB, DiFilippo FP, Neumann DR, Tang WHW, Erzurum SC.

JCI Insight. 2017 Aug 17;2(16). pii: 95240. doi: 10.1172/jci.insight.95240. [Epub ahead of print]

4.

β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction.

Dondo TB, Hall M, West RM, Jernberg T, Lindahl B, Bueno H, Danchin N, Deanfield JE, Hemingway H, Fox KAA, Timmis AD, Gale CP.

J Am Coll Cardiol. 2017 Jun 6;69(22):2710-2720. doi: 10.1016/j.jacc.2017.03.578.

5.

Mean Platelet Volume as a Predictor of Heart Failure-Related Hospitalizations in Stable Heart Failure Outpatients with Sinus Rhythm.

Kaya H, Kutay Yıldırımlı M, Kurt R, Beton O, Birhan Yilmaz M.

Acta Cardiol Sin. 2017 May;33(3):292-300.

6.

Enhancing Cardiac Resynchronization Therapy for Patients with Atrial Fibrillation: The Role of AV Node Ablation.

M Berry J, AJoglar J.

J Atr Fibrillation. 2012 Apr 14;4(6):438. doi: 10.4022/jafib.438. eCollection 2012 Apr-May. Review.

7.

Effects of carvedilol on structural and functional outcomes and plasma biomarkers in the mouse transverse aortic constriction heart failure model.

Hampton C, Rosa R, Szeto D, Forrest G, Campbell B, Kennan R, Wang S, Huang CH, Gichuru L, Ping X, Shen X, Small K, Madwed J, Lynch JJ.

SAGE Open Med. 2017 Mar 30;5:2050312117700057. doi: 10.1177/2050312117700057. eCollection 2017.

8.

E2/ER β Enhances Calcineurin Protein Degradation and PI3K/Akt/MDM2 Signal Transduction to Inhibit ISO-Induced Myocardial Cell Apoptosis.

Lin KH, Kuo WW, Shibu MA, Day CH, Hsieh YL, Chung LC, Chen RJ, Wen SY, Viswanadha VP, Huang CY.

Int J Mol Sci. 2017 Apr 24;18(4). pii: E892. doi: 10.3390/ijms18040892.

9.

The Real Role of β-Blockers in Daily Cardiovascular Therapy.

Dézsi CA, Szentes V.

Am J Cardiovasc Drugs. 2017 Oct;17(5):361-373. doi: 10.1007/s40256-017-0221-8. Review.

10.

Impact of metoprolol treatment on mental status of chronic heart failure patients with neuropsychiatric disorders.

Liu X, Lou X, Cheng X, Meng Y.

Drug Des Devel Ther. 2017 Jan 25;11:305-312. doi: 10.2147/DDDT.S124497. eCollection 2017.

11.
13.

Metoprolol Improves Endothelial Function in Patients with Cardiac Syndrome X.

Majidinia M, Rasmi Y, Khadem Ansari MH, Seyed-Mohammadzad M, Saboory E, Shirpoor A.

Iran J Pharm Res. 2016 Summer;15(3):561-566.

14.

Management Of Atrial Fibrillation In Patients With Heart Failure.

E Darby Md A.

J Atr Fibrillation. 2014 Aug 31;7(2):1105. doi: 10.4022/jafib.1105. eCollection 2014 Aug-Sep. Review.

15.

Long-term use of secondary prevention medications for heart failure in Western Australia: a protocol for a population-based cohort study.

Qin X, Teng TK, Hung J, Briffa T, Sanfilippo FM.

BMJ Open. 2016 Nov 1;6(11):e014397. doi: 10.1136/bmjopen-2016-014397.

16.

Incremental Value of Speckle Tracking Echocardiography to Predict Cardiac Resynchronization Therapy (CRT) Responders.

Seo Y, Ishizu T, Machino-Ohtsuka T, Yamamoto M, Machino T, Kuroki K, Yamasaki H, Sekiguchi Y, Nogami A, Aonuma K.

J Am Heart Assoc. 2016 Oct 19;5(10). pii: e003882.

17.

A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure.

Iyngkaran P, Toukhsati SR, Thomas MC, Jelinek MV, Hare DL, Horowitz JD.

Clin Med Insights Cardiol. 2016 Oct 12;10:163-171. eCollection 2016. Review.

18.

β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocol.

Bhatt SP, Connett JE, Voelker H, Lindberg SM, Westfall E, Wells JM, Lazarus SC, Criner GJ, Dransfield MT.

BMJ Open. 2016 Jun 7;6(6):e012292. doi: 10.1136/bmjopen-2016-012292.

19.

Discovery of Genetic Variation on Chromosome 5q22 Associated with Mortality in Heart Failure.

Smith JG, Felix JF, Morrison AC, Kalogeropoulos A, Trompet S, Wilk JB, Gidlöf O, Wang X, Morley M, Mendelson M, Joehanes R, Ligthart S, Shan X, Bis JC, Wang YA, Sjögren M, Ngwa J, Brandimarto J, Stott DJ, Aguilar D, Rice KM, Sesso HD, Demissie S, Buckley BM, Taylor KD, Ford I, Yao C, Liu C; CHARGE-SCD consortium; EchoGen consortium; QT-IGC consortium; CHARGE-QRS consortium, Sotoodehnia N, van der Harst P, Stricker BH, Kritchevsky SB, Liu Y, Gaziano JM, Hofman A, Moravec CS, Uitterlinden AG, Kellis M, van Meurs JB, Margulies KB, Dehghan A, Levy D, Olde B, Psaty BM, Cupples LA, Jukema JW, Djousse L, Franco OH, Boerwinkle E, Boyer LA, Newton-Cheh C, Butler J, Vasan RS, Cappola TP, Smith NL.

PLoS Genet. 2016 May 5;12(5):e1006034. doi: 10.1371/journal.pgen.1006034. eCollection 2016 May.

20.

Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis.

Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, Collins PD, Packer M, Wikstrand J, Coats AJ, Cleland JG, Kirchhof P, von Lueder TG, Rigby AS, Andersson B, Lip GY, van Veldhuisen DJ, Shibata MC, Wedel H, Böhm M, Flather MD; Beta-Blockers in Heart Failure Collaborative Group.

BMJ. 2016 Apr 20;353:i1855. doi: 10.1136/bmj.i1855. Review.

Supplemental Content

Support Center